QuantumScape Stories Third Quarter 2022 Enterprise and Monetary Outcomes

Press launch content material from Enterprise Wire. The AP information workers was not concerned in its creation.

SAN JOSE, Calif.–(BUSINESS WIRE)–Oct 26, 2022–

QuantumScape Company (NYSE: QS), a frontrunner within the growth of next-generation solid-state lithium-metal batteries, as we speak introduced its enterprise and monetary outcomes for the third quarter of 2022, which ended September 30.

The corporate posted a letter to shareholders on its Investor Relations web site, ir.quantumscape.com, that particulars third-quarter monetary outcomes and gives a enterprise replace.

QuantumScape will host a reside webcast as we speak at 2:00 p.m. Pacific Time

Read More Read More

Aspen Aerogels, Inc. Experiences Third Quarter 2022 Monetary Outcomes and Latest Enterprise Developments

NORTHBOROUGH, Mass., Oct. 26, 2022 /PRNewswire/ — Aspen Aerogels, Inc. (NYSE: ASPN) (“Aspen” or the “Firm”), a know-how chief in sustainability and electrification options, at this time introduced monetary outcomes for the third quarter of 2022, which ended September 30, 2022, and mentioned latest enterprise developments.

Complete income for the third quarter of 2022 was $36.7 million, in comparison with $30.4 million within the third quarter final 12 months. Third quarter internet loss was $29.6 million, in comparison with a internet lack of $7.8 million within the third quarter of 2021. Internet loss per

Read More Read More

Bambuser Continued Sturdy Enterprise Momentum within the Second Quarter with ARR Development of 118% Yr on Yr

STOCKHOLM, SWEDEN / ACCESSWIRE / July 27, 2022 / Bambuser AB (STO:BUSER)(FRA:5JL)

Bambuser reported a strong ARR of 120,1 MSEK, a rise of 118% in comparison with final yr. The expansion was primarily pushed by sturdy demand from enterprise prospects in North America and Europe. The money steadiness closed at 442,7 MSEK, adequate to take Bambuser to constructive money circulate.

The second quarter included important new contracts, expansions, and renewals with manufacturers corresponding to Shiseido, LVMH, Nars, Samsung Electronics UK, and Leroy Merlin. Compelling consumer information additional demonstrated the sturdy adoption pattern with the variety of distinctive viewers growing 286%

Read More Read More

Nicox Offers Second Quarter 2022 Monetary and Enterprise Highlights

  • Enrollment accomplished within the NCX 470 Mont Blanc Section 3 trial in glaucoma with topline outcomes anticipated in November 2022

  • Second quarter 2022 U.S. prescriptions for VYZULTA® elevated by 35% over second quarter 2021

  • Internet revenue 0.7 million for second quarter 2022; money of €31.6 million on June 30, 2022

July 20, 2022 – launch at 7:30 am CET
Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX), a global ophthalmology firm, right now supplied monetary and enterprise highlights for second quarter 2022 for Nicox SA and its subsidiaries (the “Nicox Group”) and

Read More Read More

Wave Life Sciences Studies Fourth Quarter and Full Yr 2021 Monetary Outcomes and Supplies Enterprise Replace

Wave Life Sciences USA, Inc.

Medical information from a number of novel, PN-modified stereopure oligonucleotides for ALS/FTD, DMD, and HD anticipated in 2022

GalNAc-AIMers restore therapeutically related ranges of AAT for lung safety and scale back liver-damaging aggregates in preclinical examine; IND enabling toxicology research anticipated to provoke in 3Q 2022

FY2021 year-end money whole of $150.6 million offering runway into 2Q 2023

Wave to host investor convention name and webcast at 8:30 a.m. ET at present

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines firm dedicated to delivering life-changing

Read More Read More

Cellectis Offers Enterprise Replace and Reviews 4th Quarter and Full Yr 2021 Monetary Outcomes

Cellectis Inc.

  • On monitor for deliberate 2022 IND submission for UCART20x22, our first allogeneic twin CAR T-cell product candidate, in B-cell non-Hodgkin’s Lymphoma

  • Two manufacturing websites at the moment are totally operational; on-track to dose sufferers with investigational medicinal merchandise manufactured in-house in 2022

  • Money place1 of $191 million as of December 31, 2021

  • Convention name scheduled for 8AM ET/2PM CET on March 4, 2022

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) — Cellectis (Euronext Progress: ALCLS – Nasdaq: CLLS), a clinical-stage biotechnology firm utilizing its pioneering gene-editing platform to develop doubtlessly life-saving cell and gene therapies, introduced its

Read More Read More